SCHEMBL650073

SCHEMBL650073

CCCCN(Cc1ccc2c(O)ncnc2c1)Cc1c(-c2ccccc2)nc(-c2ccccc2)n1CCCC

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.43
TSHR P16473 3/20 0.35
HDAC1 Q13547 1/20 0.34
BCHE P06276 1/20 0.34
CRHR1 P34998 2/20 0.34
ATP4A P20648 2/20 0.34
ATP4B P51164 2/20 0.34
KDM4E B2RXH2 3/20 0.33
ALDH1A1 P00352 2/20 0.33
CYP3A4 P08684 2/20 0.33
HPGD P15428 2/20 0.33
HSD17B10 Q99714 2/20 0.33
AGTR1 P30556 1/20 0.33
PPARG P37231 1/20 0.33
DRD2 P14416 2/20 0.33
DRD3 P35462 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1913062 0.92 C5AR1 (0.38) C5AR1TSHRBCHECRHR1KDM4E
SCHEMBL649867 0.88 C5AR1 (0.59) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL649712 0.83 C5AR1 (0.49) C5AR1TSHRHDAC1BCHECRHR1
SCHEMBL5136942 0.83 C5AR1 (0.46) C5AR1TSHRHDAC1CRHR1ATP4A
SCHEMBL653253 0.82 HSP90AA1 (0.41) C5AR1
SCHEMBL5136826 0.82 OPRM1 (0.47) C5AR1TSHRHDAC1BCHECRHR1
SCHEMBL5137489 0.81 C5AR1 (0.48) C5AR1TSHRCRHR1ATP4AATP4B
SCHEMBL650018 0.81 C5AR1 (0.46) C5AR1TSHRHDAC1BCHECRHR1
SCHEMBL650777 0.81 C5AR1 (0.46) C5AR1TSHRHDAC1BCHECRHR1
SCHEMBL649161 0.81 C5AR1 (0.47) C5AR1TSHRBCHECRHR1ATP4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed